GB2269170A — Azatricyclic tachykinin antagonists

USPTO Abstract

Compounds of formula (I), and salts and prodrugs thereof: <IMAGE> wherein Q, together with the C-C-N skeleton depicted in the formula, is an optionally substituted azatricyclic ring system; X represents O, S, CH2 or =CH-; Y represents H, OH, =O or halo; R<1> represents phenyl (optionally substituted by halo or trifluoromethyl) or a group CWR<6>R<7>; R<3>, R<4> and R<5> independently represent H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR<a>, SCH3, SOCH3, SO2 CH3, -NR<a>R<b>, -NR<a>COR<b>, -NRaCo2 Rb, -CO2R<a> or -CONR<a>R<b>; R<a> and R<b> independently represent H, C1-6 alkyl, phenyl or trifluoromethyl; W represents H or hydroxy; R<6> represents furyl, thienyl, pyridyl, indolyl, biphenyl or phenyl (each optionally substituted by one or two substituents selected from halo, trifluoromethyl, C1-3 alkyl, C1-3 alkoxy, and CO2R<c>, where R<c> is H, C1-3 alkyl or benzyl); R<7> represents thienyl or phenyl optionally substituted by halo or trifluoromethyl; with the proviso that when X is O or S, Y is H are tachykinin receptor antagonists useful in therapy.